Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System

The objectives of this study were (i) to explore whether differences in cell proliferation may help explain why most high-grade serous ovarian cancers (HGSOC) arise in the fallopian tube fimbriae (FTF) rather than in ovarian cortical inclusion cysts (CIC); (ii) to compare premenopausal and postmenop...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer epidemiology, biomarkers & prevention biomarkers & prevention, 2022-09, Vol.31 (9), p.1823-1829
Hauptverfasser: Park, Kay J, Broach, Vance, Chi, Dennis S, Linkov, Irina, Stanczyk, Frank Z, Patel, Prusha, Jotwani, Anjali, Pearce, Celeste Leigh, Pike, Malcolm C, Kauff, Noah D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 1829
container_issue 9
container_start_page 1823
container_title Cancer epidemiology, biomarkers & prevention
container_volume 31
creator Park, Kay J
Broach, Vance
Chi, Dennis S
Linkov, Irina
Stanczyk, Frank Z
Patel, Prusha
Jotwani, Anjali
Pearce, Celeste Leigh
Pike, Malcolm C
Kauff, Noah D
description The objectives of this study were (i) to explore whether differences in cell proliferation may help explain why most high-grade serous ovarian cancers (HGSOC) arise in the fallopian tube fimbriae (FTF) rather than in ovarian cortical inclusion cysts (CIC); (ii) to compare premenopausal and postmenopausal FTF proliferation as a reason why the age incidence of HGSOC increases at a slower rate after menopause; and (iii) to compare FTF proliferation in cycling women and women using the levonorgestrel intrauterine contraceptive system (Lng-IUS) to see whether proliferation on the Lng-IUS was lower. We studied 60 women undergoing a salpingo-oophorectomy. We used Ki67, paired-box gene 8 (PAX8, Müllerian marker), and calretinin (mesothelial marker) to study FTF and CIC proliferation. FTF Ki67%+ was greater in the follicular than in the luteal phase (4.9% vs. 1.5%; P = 0.003); postmenopausal Ki67%+ was 1.7%. Ki67%+ in PAX8 negative (PAX8-) CICs was extremely low. Proliferation in PAX8+ CICs did not vary by menstrual phase or menopausal status. Follicular Ki67%+ was 2.6-fold higher in FTF than PAX8+ CICs. FTF Ki67%+ from 10 women using the Lng-IUS was not lower than in cycling women. Overall FTF Ki67%+ is greater than overall CIC Ki67%+. Overall FTF Ki67%+ in postmenopausal women is lower than in premenopausal women. The Lng-IUS is not associated with lower FTF Ki67%+. Ki67%+ provides an explanation of the preponderance of FTF-derived HGSOCs, and of the slower increase of HGSOCs after menopause. The Lng-IUS may not be associated with a protective effect against HGSOCs.
doi_str_mv 10.1158/1055-9965.EPI-22-0217
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2676554472</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2676554472</sourcerecordid><originalsourceid>FETCH-LOGICAL-c304t-c1a38a00ceff5a2b794f800abeb091e08995edf2d935235d21b59fb1844f78ff3</originalsourceid><addsrcrecordid>eNo9kVFvFCEUhUmjaWvrT9Dw6MtUYOYug29mstVN1tjE9pkwzEUxM8MKTJP9O_5SmWzXJzhwzge5h5B3nN1xDu1HzgAqpTZwt33YVUJUTHB5Qa451G0lJcCrsj97rsiblH4zxqQCuCRXNcgiuLwmfx9iGL3DaLIPMw2O5l9I7804hoM3M31c-iL91EdvkJp5oF2I2Vsz0t1sxyWtqe6YcvpEt86hzekM-YZzynEpzu5ox1N4Pd_jc5hD_InlFldMjmbJGP2MBb4qi4fsn5H-KFycbslrZ8aEb1_WG_J0v33svlb771923ed9ZWvW5MpyU7eGMYvOgRG9VI1rGTM99kxxZK1SgIMTg6pB1DAI3oNyPW-bxsnWufqGfDhxDzH8Wcrv9OSTxXE0M4YlabGRG4CmkaJY4WS1MaQU0elD9JOJR82ZXuvR6-j1Onpd6tFC6LWeknv_8sTSTzj8T537qP8B8eePJw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2676554472</pqid></control><display><type>article</type><title>Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Park, Kay J ; Broach, Vance ; Chi, Dennis S ; Linkov, Irina ; Stanczyk, Frank Z ; Patel, Prusha ; Jotwani, Anjali ; Pearce, Celeste Leigh ; Pike, Malcolm C ; Kauff, Noah D</creator><creatorcontrib>Park, Kay J ; Broach, Vance ; Chi, Dennis S ; Linkov, Irina ; Stanczyk, Frank Z ; Patel, Prusha ; Jotwani, Anjali ; Pearce, Celeste Leigh ; Pike, Malcolm C ; Kauff, Noah D</creatorcontrib><description>The objectives of this study were (i) to explore whether differences in cell proliferation may help explain why most high-grade serous ovarian cancers (HGSOC) arise in the fallopian tube fimbriae (FTF) rather than in ovarian cortical inclusion cysts (CIC); (ii) to compare premenopausal and postmenopausal FTF proliferation as a reason why the age incidence of HGSOC increases at a slower rate after menopause; and (iii) to compare FTF proliferation in cycling women and women using the levonorgestrel intrauterine contraceptive system (Lng-IUS) to see whether proliferation on the Lng-IUS was lower. We studied 60 women undergoing a salpingo-oophorectomy. We used Ki67, paired-box gene 8 (PAX8, Müllerian marker), and calretinin (mesothelial marker) to study FTF and CIC proliferation. FTF Ki67%+ was greater in the follicular than in the luteal phase (4.9% vs. 1.5%; P = 0.003); postmenopausal Ki67%+ was 1.7%. Ki67%+ in PAX8 negative (PAX8-) CICs was extremely low. Proliferation in PAX8+ CICs did not vary by menstrual phase or menopausal status. Follicular Ki67%+ was 2.6-fold higher in FTF than PAX8+ CICs. FTF Ki67%+ from 10 women using the Lng-IUS was not lower than in cycling women. Overall FTF Ki67%+ is greater than overall CIC Ki67%+. Overall FTF Ki67%+ in postmenopausal women is lower than in premenopausal women. The Lng-IUS is not associated with lower FTF Ki67%+. Ki67%+ provides an explanation of the preponderance of FTF-derived HGSOCs, and of the slower increase of HGSOCs after menopause. The Lng-IUS may not be associated with a protective effect against HGSOCs.</description><identifier>ISSN: 1055-9965</identifier><identifier>EISSN: 1538-7755</identifier><identifier>DOI: 10.1158/1055-9965.EPI-22-0217</identifier><identifier>PMID: 35700017</identifier><language>eng</language><publisher>United States</publisher><subject>Cell Proliferation ; Contraceptive Agents ; Cysts ; Fallopian Tubes ; Female ; Humans ; Intrauterine Devices, Medicated ; Ki-67 Antigen ; Levonorgestrel - pharmacology ; Menstrual Cycle</subject><ispartof>Cancer epidemiology, biomarkers &amp; prevention, 2022-09, Vol.31 (9), p.1823-1829</ispartof><rights>2022 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c304t-c1a38a00ceff5a2b794f800abeb091e08995edf2d935235d21b59fb1844f78ff3</cites><orcidid>0000-0002-1219-8857 ; 0000-0002-8023-7846 ; 0000-0001-8989-2938 ; 0000-0001-9688-8873 ; 0000-0001-7520-5359 ; 0000-0002-3843-5398 ; 0000-0003-4891-1199 ; 0000-0001-7242-6156 ; 0000-0002-3607-121X ; 0000-0002-3105-8913</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35700017$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Kay J</creatorcontrib><creatorcontrib>Broach, Vance</creatorcontrib><creatorcontrib>Chi, Dennis S</creatorcontrib><creatorcontrib>Linkov, Irina</creatorcontrib><creatorcontrib>Stanczyk, Frank Z</creatorcontrib><creatorcontrib>Patel, Prusha</creatorcontrib><creatorcontrib>Jotwani, Anjali</creatorcontrib><creatorcontrib>Pearce, Celeste Leigh</creatorcontrib><creatorcontrib>Pike, Malcolm C</creatorcontrib><creatorcontrib>Kauff, Noah D</creatorcontrib><title>Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System</title><title>Cancer epidemiology, biomarkers &amp; prevention</title><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><description>The objectives of this study were (i) to explore whether differences in cell proliferation may help explain why most high-grade serous ovarian cancers (HGSOC) arise in the fallopian tube fimbriae (FTF) rather than in ovarian cortical inclusion cysts (CIC); (ii) to compare premenopausal and postmenopausal FTF proliferation as a reason why the age incidence of HGSOC increases at a slower rate after menopause; and (iii) to compare FTF proliferation in cycling women and women using the levonorgestrel intrauterine contraceptive system (Lng-IUS) to see whether proliferation on the Lng-IUS was lower. We studied 60 women undergoing a salpingo-oophorectomy. We used Ki67, paired-box gene 8 (PAX8, Müllerian marker), and calretinin (mesothelial marker) to study FTF and CIC proliferation. FTF Ki67%+ was greater in the follicular than in the luteal phase (4.9% vs. 1.5%; P = 0.003); postmenopausal Ki67%+ was 1.7%. Ki67%+ in PAX8 negative (PAX8-) CICs was extremely low. Proliferation in PAX8+ CICs did not vary by menstrual phase or menopausal status. Follicular Ki67%+ was 2.6-fold higher in FTF than PAX8+ CICs. FTF Ki67%+ from 10 women using the Lng-IUS was not lower than in cycling women. Overall FTF Ki67%+ is greater than overall CIC Ki67%+. Overall FTF Ki67%+ in postmenopausal women is lower than in premenopausal women. The Lng-IUS is not associated with lower FTF Ki67%+. Ki67%+ provides an explanation of the preponderance of FTF-derived HGSOCs, and of the slower increase of HGSOCs after menopause. The Lng-IUS may not be associated with a protective effect against HGSOCs.</description><subject>Cell Proliferation</subject><subject>Contraceptive Agents</subject><subject>Cysts</subject><subject>Fallopian Tubes</subject><subject>Female</subject><subject>Humans</subject><subject>Intrauterine Devices, Medicated</subject><subject>Ki-67 Antigen</subject><subject>Levonorgestrel - pharmacology</subject><subject>Menstrual Cycle</subject><issn>1055-9965</issn><issn>1538-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kVFvFCEUhUmjaWvrT9Dw6MtUYOYug29mstVN1tjE9pkwzEUxM8MKTJP9O_5SmWzXJzhwzge5h5B3nN1xDu1HzgAqpTZwt33YVUJUTHB5Qa451G0lJcCrsj97rsiblH4zxqQCuCRXNcgiuLwmfx9iGL3DaLIPMw2O5l9I7804hoM3M31c-iL91EdvkJp5oF2I2Vsz0t1sxyWtqe6YcvpEt86hzekM-YZzynEpzu5ox1N4Pd_jc5hD_InlFldMjmbJGP2MBb4qi4fsn5H-KFycbslrZ8aEb1_WG_J0v33svlb771923ed9ZWvW5MpyU7eGMYvOgRG9VI1rGTM99kxxZK1SgIMTg6pB1DAI3oNyPW-bxsnWufqGfDhxDzH8Wcrv9OSTxXE0M4YlabGRG4CmkaJY4WS1MaQU0elD9JOJR82ZXuvR6-j1Onpd6tFC6LWeknv_8sTSTzj8T537qP8B8eePJw</recordid><startdate>20220902</startdate><enddate>20220902</enddate><creator>Park, Kay J</creator><creator>Broach, Vance</creator><creator>Chi, Dennis S</creator><creator>Linkov, Irina</creator><creator>Stanczyk, Frank Z</creator><creator>Patel, Prusha</creator><creator>Jotwani, Anjali</creator><creator>Pearce, Celeste Leigh</creator><creator>Pike, Malcolm C</creator><creator>Kauff, Noah D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-1219-8857</orcidid><orcidid>https://orcid.org/0000-0002-8023-7846</orcidid><orcidid>https://orcid.org/0000-0001-8989-2938</orcidid><orcidid>https://orcid.org/0000-0001-9688-8873</orcidid><orcidid>https://orcid.org/0000-0001-7520-5359</orcidid><orcidid>https://orcid.org/0000-0002-3843-5398</orcidid><orcidid>https://orcid.org/0000-0003-4891-1199</orcidid><orcidid>https://orcid.org/0000-0001-7242-6156</orcidid><orcidid>https://orcid.org/0000-0002-3607-121X</orcidid><orcidid>https://orcid.org/0000-0002-3105-8913</orcidid></search><sort><creationdate>20220902</creationdate><title>Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System</title><author>Park, Kay J ; Broach, Vance ; Chi, Dennis S ; Linkov, Irina ; Stanczyk, Frank Z ; Patel, Prusha ; Jotwani, Anjali ; Pearce, Celeste Leigh ; Pike, Malcolm C ; Kauff, Noah D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c304t-c1a38a00ceff5a2b794f800abeb091e08995edf2d935235d21b59fb1844f78ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Cell Proliferation</topic><topic>Contraceptive Agents</topic><topic>Cysts</topic><topic>Fallopian Tubes</topic><topic>Female</topic><topic>Humans</topic><topic>Intrauterine Devices, Medicated</topic><topic>Ki-67 Antigen</topic><topic>Levonorgestrel - pharmacology</topic><topic>Menstrual Cycle</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Kay J</creatorcontrib><creatorcontrib>Broach, Vance</creatorcontrib><creatorcontrib>Chi, Dennis S</creatorcontrib><creatorcontrib>Linkov, Irina</creatorcontrib><creatorcontrib>Stanczyk, Frank Z</creatorcontrib><creatorcontrib>Patel, Prusha</creatorcontrib><creatorcontrib>Jotwani, Anjali</creatorcontrib><creatorcontrib>Pearce, Celeste Leigh</creatorcontrib><creatorcontrib>Pike, Malcolm C</creatorcontrib><creatorcontrib>Kauff, Noah D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Cancer epidemiology, biomarkers &amp; prevention</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Kay J</au><au>Broach, Vance</au><au>Chi, Dennis S</au><au>Linkov, Irina</au><au>Stanczyk, Frank Z</au><au>Patel, Prusha</au><au>Jotwani, Anjali</au><au>Pearce, Celeste Leigh</au><au>Pike, Malcolm C</au><au>Kauff, Noah D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System</atitle><jtitle>Cancer epidemiology, biomarkers &amp; prevention</jtitle><addtitle>Cancer Epidemiol Biomarkers Prev</addtitle><date>2022-09-02</date><risdate>2022</risdate><volume>31</volume><issue>9</issue><spage>1823</spage><epage>1829</epage><pages>1823-1829</pages><issn>1055-9965</issn><eissn>1538-7755</eissn><abstract>The objectives of this study were (i) to explore whether differences in cell proliferation may help explain why most high-grade serous ovarian cancers (HGSOC) arise in the fallopian tube fimbriae (FTF) rather than in ovarian cortical inclusion cysts (CIC); (ii) to compare premenopausal and postmenopausal FTF proliferation as a reason why the age incidence of HGSOC increases at a slower rate after menopause; and (iii) to compare FTF proliferation in cycling women and women using the levonorgestrel intrauterine contraceptive system (Lng-IUS) to see whether proliferation on the Lng-IUS was lower. We studied 60 women undergoing a salpingo-oophorectomy. We used Ki67, paired-box gene 8 (PAX8, Müllerian marker), and calretinin (mesothelial marker) to study FTF and CIC proliferation. FTF Ki67%+ was greater in the follicular than in the luteal phase (4.9% vs. 1.5%; P = 0.003); postmenopausal Ki67%+ was 1.7%. Ki67%+ in PAX8 negative (PAX8-) CICs was extremely low. Proliferation in PAX8+ CICs did not vary by menstrual phase or menopausal status. Follicular Ki67%+ was 2.6-fold higher in FTF than PAX8+ CICs. FTF Ki67%+ from 10 women using the Lng-IUS was not lower than in cycling women. Overall FTF Ki67%+ is greater than overall CIC Ki67%+. Overall FTF Ki67%+ in postmenopausal women is lower than in premenopausal women. The Lng-IUS is not associated with lower FTF Ki67%+. Ki67%+ provides an explanation of the preponderance of FTF-derived HGSOCs, and of the slower increase of HGSOCs after menopause. The Lng-IUS may not be associated with a protective effect against HGSOCs.</abstract><cop>United States</cop><pmid>35700017</pmid><doi>10.1158/1055-9965.EPI-22-0217</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-1219-8857</orcidid><orcidid>https://orcid.org/0000-0002-8023-7846</orcidid><orcidid>https://orcid.org/0000-0001-8989-2938</orcidid><orcidid>https://orcid.org/0000-0001-9688-8873</orcidid><orcidid>https://orcid.org/0000-0001-7520-5359</orcidid><orcidid>https://orcid.org/0000-0002-3843-5398</orcidid><orcidid>https://orcid.org/0000-0003-4891-1199</orcidid><orcidid>https://orcid.org/0000-0001-7242-6156</orcidid><orcidid>https://orcid.org/0000-0002-3607-121X</orcidid><orcidid>https://orcid.org/0000-0002-3105-8913</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1055-9965
ispartof Cancer epidemiology, biomarkers & prevention, 2022-09, Vol.31 (9), p.1823-1829
issn 1055-9965
1538-7755
language eng
recordid cdi_proquest_miscellaneous_2676554472
source MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Cell Proliferation
Contraceptive Agents
Cysts
Fallopian Tubes
Female
Humans
Intrauterine Devices, Medicated
Ki-67 Antigen
Levonorgestrel - pharmacology
Menstrual Cycle
title Proliferation of the Fallopian Tube Fimbriae and Cortical Inclusion Cysts: Effects of the Menstrual Cycle and the Levonorgestrel Intrauterine Contraceptive System
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T13%3A14%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Proliferation%20of%20the%20Fallopian%20Tube%20Fimbriae%20and%20Cortical%20Inclusion%20Cysts:%20Effects%20of%20the%20Menstrual%20Cycle%20and%20the%20Levonorgestrel%20Intrauterine%20Contraceptive%20System&rft.jtitle=Cancer%20epidemiology,%20biomarkers%20&%20prevention&rft.au=Park,%20Kay%20J&rft.date=2022-09-02&rft.volume=31&rft.issue=9&rft.spage=1823&rft.epage=1829&rft.pages=1823-1829&rft.issn=1055-9965&rft.eissn=1538-7755&rft_id=info:doi/10.1158/1055-9965.EPI-22-0217&rft_dat=%3Cproquest_cross%3E2676554472%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2676554472&rft_id=info:pmid/35700017&rfr_iscdi=true